drugset
drugset / Trial / NCT03977727

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

NCT03977727 ↗

Phase 3 Completed 40 enrolled Texas Diabetes & Endocrinology, P.A.
RandomizedCrossoverOpen-labelTreatment

Summary

This is an exploratory, single-center, randomized, open label, active-controlled, complete cross-over trial comparing safety and efficacy of Fiasp® versus NovoLog® when used in the Medtronic MiniMed 670G system in subjects with T1DM.

Timeline

Start
2019-06-11
Primary completion
2020-03-09
Completion
2020-04-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fast-acting insulin aspart Protein / enzyme biologic — Subcutaneous
Subject insulin aspart Protein / enzyme biologic — Subcutaneous

Indications

type 1 diabetes mellitus